The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?

Current Breast Cancer Reports

Volumn 9, Issue 1, 2017, Pages 45-51

  Hu, Zishuo I ^a   McArthur, Heather L ^b   Ho, Alice Y ^b  

^a MOUNT SINAI HEALTH SYSTEM   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Abscopal effect; Breast cancer; Immunotherapy; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; DURVALUMAB; GALUNISERTIB; IMIQUIMOD; INTERLEUKIN 2; MEDI 6469; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ABSCOPAL EFFECT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE CHECKPOINT; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; IMMUNOSTIMULATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOACTIVITY; REVIEW; TUMOR MICROENVIRONMENT;

EID: 85014090264     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-017-0234-y     Document Type: Review

References (57)

1. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26:234–41.
2. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41:503–10.
3. Steel GG, McMillan TJ, Peacock JH. The 5Rs of radiobiology. Int J Radiat Biol. 1989;56:1045–8.
4. Grilli G, Nothdurft W, Fliedner TM. Radiation sensitivity of human erythropoietic and granulopoietic progenitor cells in the blood and in the bone marrow. Int J Radiat Biol Relat Stud Phys Chem Med. 1982;41(6):685–7.
5. Deeg HJ, Sullivan KM, Buckner CD, Storb R, Appelbaum FR, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant. 1986;1(2):151–7.
6. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409–25.
7. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5:403–16.
8. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61.
9. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192:565–70.
10. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47–59.
11. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.
12. Toll-like receptor (TLR) 7 agonist, cyclophosphamide, and radiotherapy for breast cancer with skin metastases. 2016. at https://clinicaltrials.gov/ct2/show/NCT01421017
13. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15:1170–8.
14. Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843–52.
15. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170:6338–47.
16. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64:7985–94.
17. Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res. 1996;56:5150–5.
18. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180:3132–9.
19. Matsumura S, Wang B, Kawashima N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181:3099–107.
20. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259–71.
21. Ruocco MG, Pilones KA, Kawashima N, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest. 2012;122:3718–30.
22. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002;62:1462–70.
23. Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24:589–602.
24. Kachikwu EL, Iwamoto KS, Liao YP, et al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys. 2011;81:1128–35.
25. Toivonen P, Kivela T. Infiltrating macrophages in extratumoural tissues after brachytherapy of uveal melanoma. Acta Ophthalmol. 2012;90:341–9.
26. Julow J, Szeifert GT, Balint K, Nyary I, Nemes Z. The role of microglia/macrophage system in the tissue response to I-125 interstitial brachytherapy of cerebral gliomas. Neurol Res. 2007;29:233–8.
27. Vatner RE, Formenti SC. Myeloid-derived cells in tumors: effects of radiation. Semin Radiat Oncol. 2015;25:18–27.
28. Dybal EJ, Haas GP, Maughan RL, Sud S, Pontes JE, Hillman GG. Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. J Urol. 1992;148:1331–7.
29. Yasuda K, Nirei T, Tsuno NH, Nagawa H, Kitayama J. Intratumoral injection of interleukin-2 augments the local and abscopal effects of radiotherapy in murine rectal cancer. Cancer Sci. 2011;102:1257–63.
30. Chakravarty PK, Alfieri A, Thomas EK, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res. 1999;59:6028–32.
31. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862–70.
32. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol. 2005;560:11–8.
33. Dewan MZ, Vanpouille-Box C, Kawashima N, et al. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res. 2012;18:6668–78.
34. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11:728–34.
35. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379–88.
36. Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86:343–9.
37. Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3:345–55.
38. • Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–7. The authors report that triple therapy using PD-L1 blockade, CTLA-4 blockade, and radiation work in nonredundant, complementary fashion to promote antitumor immunity. PDL-1 and CTLA-4 inhibition reverses T cell exhaustion and decreases regulatory T cells while radiation broadens the T cell receptor repertoire of TILs and shape the repertoire of the expanded peripheral clones.
39. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31.
40. Hiniker SM, Chen DS, Reddy S, et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol. 2012;5:404–7.
41. Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24:1813–21.
42. • Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795–803. The study reported that the combination of GM-CSF with radiochemotherapy resulted in abscopal responses in five (36%) of 14 patients with breast cancer. They show for the first time that the abscopal response can be induced in solid metastatic tumors by combining radiochemotherapy with immunotherapy.
43. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174:7516–23.
44. Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21(16):3727–39.
45. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458–68.
46. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114:589–95.
47. Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015;4:e1046028.
48. Demaria S, Formenti SC. Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? J Immunother Cancer. 2016;4:29.
49. Study to assess the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer patients. 2016. at (https://clinicaltrials.gov/ct2/show/NCT02730130.)
50. Trial of hypofractionated radiotherapy in combination with MEDI4736 and tremelimumab for patients with metastatic melanoma and lung, breast and pancreatic cancers. 2016. at (https://clinicaltrials.gov/ct2/show/NCT02639026.)
51. Nivolumab after induction treatment in triple-negative breast cancer (TNBC) patients (TONIC). 2016. at (https://clinicaltrials.gov/ct2/show/NCT02499367.)
52. Pilot study of stereotactic ablation for oligometastatic breast neoplasia in combination with the anti-PD-1 antibody MK-3475 (BOSTON II). 2016. at (https://clinicaltrials.gov/ct2/show/NCT02303366.)
53. LY2157299 monohydrate (LY2157299) and radiotherapy in metastatic breast cancer. 2016. at (https://clinicaltrials.gov/ct2/show/NCT02538471.)
54. Stereotactic body radiation and monoclonal antibody to OX40 (MEDI6469) in breast cancer patients with metastatic lesions (OX40 Breast).2016. at https://clinicaltrials.gov/ct2/show/NCT01862900
55. Brain irradiation and tremelimumab in metastatic breast cancer. 2016. at (https://clinicaltrials.gov/ct2/show/NCT02563925.)
56. RADVAX: a stratified phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with advanced and metastatic cancers. 2016. at https://clinicaltrials.gov/ct2/show/NCT02303990.
57. Study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors. 2016. at(https://clinicaltrials.gov/ct2/show/NCT02608385.)